KALA BIO Inc (KALA) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage...

Form 8-K - Current report

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-3 - Registration statement under Securities Act of 1933

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

KALA BIO Announces $12,500,000 Private Placement

ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities